EP1115409A4

EP1115409A4 - Composition for extending post meal satiety

Info

Publication number: EP1115409A4
Application number: EP00950624A
Authority: EP
Inventors: Robert Portman
Original assignee: Kemin Consumer Care LC
Current assignee: Kemin Consumer Care LC
Priority date: 1999-07-27
Filing date: 2000-07-25
Publication date: 2005-04-13
Also published as: EP1115409A1; WO2001017541A1; KR20010075394A; AU6370400A; JP2005336208A; AU779377B2; MXPA01003054A; AU779377C; BR0006959A; CA2348067A1; JP2003508490A

Abstract

A nutritional composition in a dry powder form including an extract of potatoes that provides a source of proteinase inhibitor that is mixed with water and ingested before a meal which extends satiety and thereby reduces appetite. The nutritional composition includes between about 10 % and about 80 % by weight of a protein, between about 10 % and about 40 % by weight of a medium to long chain fatty acid, between about 2 % and about 5 % by weight of a calcium salt, and between about 1 % and about 5 % by weight of a proteinase inhibitor provided by the extract of potatoes.

Description

COMPOSITION FOR EXTENDING POST MEAL SATIETY

BACKGROUND OF THE INVENTION Field of Invention The present invention relates to a nutritional composition for extending satiety following a meal More particularly the nutritional composition includes protein, medium and/or long chain fatty acids and calcium to stimulate the secretion of cholecystokinin a gastric peptide, and a source of proteinase inhibitor extracted from potatoes that prevents the breakdown of cholecystokinin By increasing and sustaining the levels of cholecystokinin, the present invention extends satiety

Background of the Prior Art

Over the last forty years there has been extensive research conducted on mechanisms that would extend satiety following the ingestion of a meal The benefits of such an invention have obvious utility in producing weight loss Weight loss research has focused on three areas Because the brain plays an essential role in the control of appetite, researchers have looked at various neurotransmitters, specifically, serotonin, dopamine and nor-epinephrine A number of prescription and over-the-counter products have been developed which influence these neurotransmitters, thereby reducing appetite Reducing appetite pharmacologically has a number of drawbacks, including a loss of effectiveness over a period of time Drugs that affect neurotransmitters also affect the central nervous systems and can cause jitteriness and anxiety In addition, these agents can produce cardiovascular effects that may even be fatal

A second approach has focused on slowing gastric emptying thereby creating a feeling of fullness This approach utilizes insoluble fibers, which slow the movement of food through the gastrointestinal tract The disadvantage with the use of fiber is that the quantities needed to produce an effect create an unpalatable diet as well as numerous gastrointestinal effects including bloating, gas and dian iea A third approach investigates stimulating the body's satiety mechanism. When food is consumed a peptide is released called Cholecystokinin Releasing Protein (CCK-RP). Cholecystokinin Releasing Protein then stimulates the release of cholecystokinin in the gut. Cholecystokinin has been shown to increase satiety. When cholecystokinin is released it also stimulates the release of enzymes which inactivate CCK-RP. When CCK-RP is inactivated, CCK levels drop and the feeling of satiation is diminished. Studies have shown that cholecystokinin is extremely effective in extending satiety following ingestion of a meal. Although CCK has been shown to extend satiety and reduce food intake, a major disadvantage is that it must be given intravenously. When administered orally, CCK is inactivated by gastric enzymes. This has severely limited its use as a potential weight loss agent.

A number of nutritive agents can stimulate the release of cholecystokinin. Researchers have shown that protein, fat (particularly medium chain fatty acids), and calcium stimulate the release of CCK.

United States Patent No. 4,491 ,578 discloses the oral administration of a trypsin inhibitor to stimulate satiety by stimulating the release of cholecystokinin. The trypsin inhibitor was postulated to act by inhibiting the negative feedback signal for cholecystokinin secretion. In this fashion, the trypsin inhibitor sustained levels of cholecystokinin thereby extending satiety.

A number of studies have shown that proteinase inhibitor extracted from potatoes stimulates the release of cholecystokinin. There is a definite need in the art for a nutritional intervention composition that can be taken orally, stimulate cholecystokinin levels prior to the initiation of a meal and sustain cholecystokinin levels and satiety for an extended period following consumption of a meal. An important element of this invention is the design of a product taken in a specified interval prior to the commencement of a meal. Thus, satiety levels are already enhanced before the meal, decreasing the quantity of food consumed during that meal.

SUMMARY OF THE INVENTION The present invention provides for nutritional composition in a dry powder form for extending satiety following ingestion of a meal

The dry nutritional composition includes proteins in the range of 10% to 80% The protein can be in the form of soy, whey, casein or a specific amino acid mixture containing essential amino acids or of the amino acid phenylalanine

The dry nutritional composition also includes the mineral calcium in the range of 2% to 6% The calcium can be in the form of a salt including calcium chloride, calcium carbonate, calcium lactate etc

The dry nutritional composition also includes medium and/or long chain fatty acids (Cι₂- C₂₂) in the range of 10%-40%

The dry nutritional composition also includes a source of proteinase inhibitor extracted from potatoes wherein the protease inhibitor is present in the range of 0.02%-5%

BRIEF DESCRIPTION OF THE DRAWINGS Fig 1 is a graphical representation of the responses of test subjects as to their feeling of satiety taken in fifteen minute intervals over a three and one-half hour period following a meal, showing both subjects who were administered a placebo and subjects who were administered a nutritional supplement according to the present invention

Fig 2 is a graphical representation of the responses of test subjects as to their feeling of hunger taken in fifteen minute intervals over a three and one-half hour period following a meal, showing both subjects who were administered a placebo and subjects who were administered a nutritional supplement according to the present invention

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS The nutritional composition for nutritional intervention for extending satiety includes nutritional agents being protein, medium and/or chain fatty acids, calcium, an extract of potatoes containing proteinase inhibitor, and, in a preferred form, flavoring agents and coloring agents The proteinase inhibitor is a heat stable protein present in potatoes and in extracts from potatoes and has a molecular weight of approximately 21 ,000 It is both a trypsin and chymotrypsm inhibitor, with its critical functionality being that it stimulates the release of cholecystokinin The protease inhibitor with the desired activity is present m potatoes and m more concentrated form in commercially available extracts or fractions of potatoes, such as coarse potato flour and potato fibei Specifically, coarse potato flour available from Nonpaπel Company contains approximately 0 49 mg of potato protease inhibitor two per gram, and Paselh PPC potato flour av ailable fiom Avebe Company, The Netherlands, contains about 1 35 mg potato protease inhibitor two per gram A method of extraction of a relatn el> puie proteinase inhibitor with the desired actn lty of the present invention is described m Bryant, J , Green, T R , Gurusaddalah, T , and Ryan, C A (\ 916), Bιochem 75, 3418 Experiment 1

This study was conducted with 21 subjects having a mean BMI =31 2 kg/m^" (range 27 0 - 35 8) and mean age = 30 9 years (range 22 - 45) The study was a cross over design consisting of two parts In the fiist phase the subjects were either given a placebo whose lsocaloπc composition s equal to the nutritional drink composition or the nutritional dπnk composition Both treatments were administered m 8 oz of water 15 minutes prior to the meal The meal consisted of 460 calories Subjects were required to consume the meal within 15 minutes Following the consumption of the meal subjects were asked to rate their feelings of hunger and satiety on 6 \ lsual analog scales every 15 minutes for 3 !/_• hours The nutritional drmk composition is set out below

Nutritional Drink Composition

Constituent Grams %

Whey Protein 13 00 71 5

Non-Dairy Creamer 4 00 22 0 containing 50% oleic acid

Calcium Lactate 0 635 3 5

Flavor 0 19 1 0

Color 0 05 0 3

POT 2¹ 0 30 1 7

POT 2 includes approx 1 % by weight of the proteinase inhibitor Hunger ratings following ingestion of the nutritional drink composition were significantly decreased throughout the post-meal measurement period, reaching a 30% decrease by 3 hours post meal (p=0 033) Consistent with this finding, fullness ratings were significantly greater starting 3 hours post meal (37% increase, p=0 043) No differences in subjective ratings of other hunger-related items, or in thirst, were observed between the conditions

Accordingly, an advantage of the present invention is that it provides for a nutritional intervention composition for extending satiety and reducing hunger following the termination of a meal

Experiment 2

This study was conducted with 21 subjects having a mean BMI =31 2 kg/m² (range 27 0 - 35 8) and mean age = 30 9 years (range 22 - 45) During the diet, subjects drank 8 oz (80 kcal) of the nutritional drink composition of Experiment 1 twice daily fifteen minutes before lunch and dinner The effect of the nutritional drink composition on satiety was measured in a laboratory before and in the fourth week of the diet On separate days subjects ingested the nutritional drink composition beverage or a placebo beverage (matched for volume and energy) fifteen minutes before a 350 calorie meal Subjects rated hunger and fullness on visual analog scales every 15 minutes for 3 Y₂ hours The results of the study show that after four weeks on the diet, fullness ratings after lunch were higher after the consumption of the nutritional drink composition than the placebo beverage (mean ± SD for all time intervals = 71 0 ± 17 3 vs 65 5 ± 16 7, p < 0 05) Hunger ratings were 32% lower after the protease inhibitor than the placebo beverage (10 5 ± 12 0 vs 15 4 ± 13 3, p < 0 01) There were no adverse reactions to the nutritional drink composition, and subjects reported that it helped them to reduce their food intake Weight loss was significant (2 0 ± 1 1 kg in 4 weeks, p < 0 001 )

Accordingly an advantage of the present invention is that it provides continual effectiveness over a 30-day period and by extending satiety results in significant weight loss The source of the protease inhibitor may vary depending on the particular application for the satiety extending product of the present invention For example, while coarse potato flour contains a significant amount of the protease inhibitor, it is difficult to disperse in water Those having ordinary skill in the art, following the teachings of the invention set out above can readily accomplish determining an appropriate source of protease inhibitor as well as other components that may be added to the composition to improve characteristics such as mouth feel, taste, and the like Although the description above contains many specificities, these should not be construed as limiting the scope of the invention, but as merely providing illustrations of some of the presently preferred embodiments of this invention

Claims

W 1 175 1

What is claimed is 1 A nutritional composition in a dry powder form that is mixed with water and ingested before a meal which extends satiety and thereby reduces appetite, comprising

(a) a protein comprising between about 10% and about 80% by weight of said dry composition,

(b) one or more fatty acids comprising between about 10% and about 40% by weight of said dry composition, (c) a calcium salt comprising between about 2% and about 5% by weight of said dry composition, and (d) an extract of potatoes pro iding a source of proteinase inhibitor that comprises between about 0 02% and about 5% by weight of said dry composition

2 A nutritional composition as defined in claim 1 , wherein said fatty acid comprises oleic acid

3 A nutritional composition as defined in claim 1 , further comprising a water soluble flavoring selected from the group including natural extracts and artificially produced extract components of apple, banana, cherry, cinnamon, cranberry, grape, honeydew, honey, kiwi, lemon, lime, orange, peach, peppeπnint, pineapple, raspberry, tangerine, watermelon, and wild cherry

4 A nutritional composition as defined in claiml , further comprising a colorant selected from the group including water soluble natural or artificial dyes of blue, green, orange, red, violet, and yellow

5 A nutritional composition as defined in claiml , further comprising a colorant selected from the group including iron oxide dyes, ultramarine pigments of blue, pink, red, and violet